Table 1.
Baseline demographic and anthropometric characteristics of the study population
| Characteristic | Sulfonylurea | Glinide | Biguanide | Thiazolidinedione | α-Glucosidase inhibitor | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Omarigliptin n = 126 | Placebo n = 63 | Omarigliptin n = 65 | Placebo n = 34 | Omarigliptin n = 66 | Placebo n = 33 | Omarigliptin n = 65 | Placebo n = 34 | Omarigliptin n = 67 | Placebo n = 32 | |
| Age, years | 63 ± 9 | 63 ± 11 | 59 ± 11 | 61 ± 10 | 59 ± 9 | 57 ± 9 | 61 ± 10 | 61 ± 9 | 61 ± 11 | 61 ± 11 |
| Male, n (%) | 91 (72.2) | 45 (71.4) | 46 (70.8) | 27 (79.4) | 46 (69.7) | 23 (69.7) | 42 (64.6) | 27 (79.4) | 46 (68.7) | 23 (71.9) |
| Body weight, kg | 65 ± 11 | 67 ± 14 | 68 ± 13 | 69 ± 14 | 69 ± 14 | 70 ± 12 | 72 ± 14 | 71 ± 13 | 68 ± 13 | 65 ± 11 |
| BMI, kg/m2 | 24.5 ± 3.4 | 24.8 ± 3.5 | 25.1 ± 4.3 | 25.3 ± 4.1 | 25.6 ± 4.4 | 25.9 ± 3.6 | 27.0 ± 4.2 | 27.0 ± 4.9 | 25.3 ± 4.0 | 24.4 ± 3.7 |
| HbA1c, % | 8.1 ± 0.7 | 8.1 ± 0.6 | 8.0 ± 0.6 | 8.0 ± 0.8 | 7.8 ± 0.6 | 8.0 ± 0.6 | 8.2 ± 0.8 | 7.9 ± 0.8 | 7.9 ± 0.6 | 7.9 ± 0.8 |
| Range | 6.9–10.0 | 7.1–9.6 | 6.9–10.3 | 6.7–9.8 | 6.8–9.9 | 6.9–10.2 | 7.0–10.0 | 6.8–10.5 | 6.9–9.6 | 7.0–10.1 |
| FPG, mg/dL | 165.4 ± 32.0 | 170.5 ± 34.0 | 163.5 ± 29.4 | 164.4 ± 34.7 | 155.8 ± 26.1 | 157.6 ± 20.6 | 163.4 ± 33.6 | 152.4 ± 24.5 | 157.7 ± 24.3 | 159.8 ± 30.7 |
| Duration of type 2 diabetes, years | 10.7 ± 5.6 | 11.5 ± 6.3 | 8.5 ± 6.2 | 8.3 ± 5.2 | 8.4 ± 4.8 | 6.9 ± 3.5 | 9.1 ± 6.4 | 10.3 ± 5.4 | 8.4 ± 5.5 | 9.7 ± 5.8 |
| Prior AHA use, yes | 43 (34.1) | 21 (33.3) | 9 (13.8) | 4 (11.8) | 16 (24.2) | 3 (9.1) | 19 (29.2) | 6 (17.6) | 19 (28.4) | 10 (31.3) |
Data are expressed as mean ± standard deviation or frequency [n (%)]
BMI body mass index, FPG fasting plasma glucose, AHA antihyperglycemic agent